StockNews.AI
GYRE
StockNews.AI
5 hrs

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

1. Gyre to present Phase 3 trial results of Hydronidone for liver fibrosis. 2. Results selected as a Poster of Distinction at The Liver Meeting 2025. 3. Hydronidone targets hepatic stellate cell activation in chronic hepatitis B. 4. Gyre focuses on commercializing fibrosis-first therapies across organ systems. 5. The presentation may enhance visibility and investor interest in GYRE.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical trial results generally lead to increased stock valuations, as evidenced by previous pharmaceutical companies with successful trial phases resulting in share price spikes. For instance, companies like Vertex Pharmaceuticals saw significant price increases after reporting positive phase trial outcomes.

How important is it?

The article highlights a critical milestone in GYRE's drug development process, which can significantly influence investor sentiment and interest, thereby impacting its price. Successful presentations in key industry forums often correlate with heightened market interest.

Why Short Term?

The upcoming presentation will likely impact GYRE’s stock in the near term, similar to how immediate reactions to clinical trial results can spike share prices. Historical examples include Gilead and if GYRE receives favorable feedback at The Liver Meeting, it may lead to rapid share price changes.

Related Companies

VYGRGILDAMGN
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that it will be presenting results from its positive Phase 3 clinical trial evaluating Hydronidone, a novel anti-fibrotic agent that inhibits hepatic stellate cell (HSC) activation and promotes HSC apoptosis, for the treatment of liver fibrosis in chronic hepatitis B, at The Liver Meeting® 2025, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting® 2025 is being held November 7-10, 2025, in Washington D.C. This abstract has been selected as a Poster of Distinction, and the details are below: Title: Phase 3 Trial of Hydronidone for Liver Fibrosis in Chronic Hepatitis B Presenting Author: Prof. Lungen Lu, M.D., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Session: Hepatitis B (“1187-1367”) Date/Time: Friday, November 7, 2025, 8:00 a.m. – 5:00 p.m. Eastern Time Publication Number: 1121 About Gyre Therapeutics Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY®, and development programs for F573, F528, and F230. For Investors: David ZhangGyre Therapeuticsdavid.zhang@gyretx.com

Related News